Drugs / 90Y-DOTA-3-Tyr-Octreotide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03044977 | May 2017 → Dec 2025 overdue | digestive system neuroendocrine neoplasm | David Bushnell | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90Y-DOTA-3-Tyr-Octreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03044977 ↗ |
| Known as | 90Y DOTATOC | “These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy.” NCT03044977 ↗ |
| Action | Deplete | “This kills more tumor cells and minimizes radiation-damage to healthy tissues, like the heart and lungs.” NCT03044977 ↗ |
| Modality | Protein / enzyme biologic | “a protein that targets the tumor cell (MIBG or DOTATOC)” NCT03044977 ↗ |
| Route | Intravenous | “For intravenous administration only.” NCT03044977 ↗ |